MedTrace Logo

A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

NCT01002092 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2014-09-03

No results posted yet for this study

Summary

Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.

Conditions

Interventions

DRUG

Chemotherapy

Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).

DRUG

Endostar

In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day

Sponsors & Collaborators

  • Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Sujia Wu, Dr. · Nanjing PLA General Hospital

  • Xin Shi, Dr. · Nanjing PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002092 on ClinicalTrials.gov